Back to Search Results


Evaluation and Management of an Ovarian Mass in a Patient with a Family History of Ovarian Cancer

Author: Christina Wallace Huff, M.D.

Mentor: Pamela D. Berens, MD
Editor: Abimbola Famuyide, MD, MBBS

Registered users can also download a PDF or listen to a podcast of this Pearl.
Log in now, or create a free account to access bonus Pearls features.

Increasing age is the most important risk factor for ovarian cancer in the general population, but a strong family history of breast or ovarian cancer is the most important personal risk factor.

Family history, including hereditary cancer risk assessment, should be completed for all patients. Increased risk of hereditary cancer syndromes include a first or second degree relative with breast, ovarian, peritoneal, or fallopian tube cancer, personal history of cancer, cancers diagnosed at a young age, multiple cancers in one individual, and multiple family members with the same cancer. Occurrence of certain types of cancer confer increased risk. Examples include triple negative breast cancer and lack of ERBB2, colorectal, or endometrial cancer with DNA mismatch repair deficiency.  Certain ethnic groups including Ashkenazi Jews, French Canadians, and Icelanders have higher rates of BRCA mutations. Lifetime risk of ovarian, fallopian tube, or peritoneal cancer is elevated in patients with BRCA 1 & 2 mutations, Lynch and Peutz-Jeghers syndromes. Other specific genes associated with ovarian cancer include BRIP1, RAD51C, and RAD51D.  Identification of risk factors should prompt referral for genetic counseling by a cancer genetics specialist to further assess the need for genetic testing.  

For patients with BRCA and Lynch mutations, risk-reducing bilateral salpingo-oophorectomy is recommended after completion of childbearing between ages 35 and 45, depending on the specific mutation. During risk reducing bilateral salpingo-oophorectomy, surgical techniques to assure complete removal of tubal and ovarian tissue, thorough visualization of peritoneal surfaces, and peritoneal washings should be performed. More extensive surgical pathologic sectioning to evaluate for occult malignancy is recommended. 

The presence of an adnexal mass in a patient with a suspicious family history or a personal history of a BRCA or Lynch mutation prompts a heightened suspicion for malignancy and a lower threshold for surgery. Masses that are clearly benign, such as simple cysts, or masses that exhibit highly suspicious characteristics for malignancy may not require different management in this special population.  For indeterminant adnexal masses in women at higher risk for ovarian cancer, surgery may be more appropriate than observation. Management of adnexal masses in the general population is covered in other Pearls (In women at higher risk for malignancy based on genetic mutation or family history, evaluation by pelvic ultrasound is still appropriate. Use of serum markers such as CA-125 or HE-4 may be helpful in management. Tests such as OVA-1 and ROMA are based on studies of average risk populations and may not accurately determine the risk of malignancy in a woman already at increased risk based on family history or genetic mutation.  It is advisable to have a gynecologic oncologist involved in the surgical care of these patients in case malignancy is found, regardless of serum marker results.

Further Reading:

American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology, Practice Bulletin No. 174: Evaluation and Management of Adnexal Masses. Obstet Gynecol. 2016 Nov;128(5):e210-e226. Reaffirmed 2021.

Committee on Practice Bulletins–Gynecology, Committee on Genetics, Society of Gynecologic Oncology. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.  Obstet Gynecol. 2017 Sep;130(3):e110-e126. doi: 10.1097/AOG.0000000000002296.

Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793. Obstet Gynecol. 2019 Dec;134(6):1366-1367. doi: 10.1097/AOG.0000000000003563. PMID: 31764755.

Initial Approval March 2018; Reaffirmed January 2020; Revised September 2021.


********** Notice Regarding Use ************

The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. (“SASGOG”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high-quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. SASGOG reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. SASGOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither SASGOG nor its respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Copyright 2021 The Society for Academic Specialists in General Obstetrics and Gynecology, Inc. All rights reserved.  No re-print, duplication or posting allowed without prior written consent.



Back to Search Results